Antibiotic Resistance: One of the Greatest Threats to Modern Medicine
Antibiotic resistance poses one of the most alarming public health threats of our time. According to the 2016 Review on Antimicrobial Resistance, if current trends continue unchecked, drug resistant infections could cause up to 10 million deaths per year globally by 2050, costing an estimated $100 trillion annually just to manage the consequences. That projection places antibiotic resistance alongside climate change as one of the defining challenges of the coming decades.
Understanding how this crisis developed, and what it will take to reverse it, requires looking at the behavior of bacteria, the economics of drug development, and the actions of every stakeholder in the global health system.
How Antibiotic Resistance Develops
Antibiotic resistance is fundamentally natural selection in action. When bacteria are exposed to an antibiotic that fails to eliminate all of them, the surviving organisms, those with genetic traits that allowed them to resist the drug, reproduce and spread. Over time, resistant strains dominate, rendering previously effective treatments useless.
Several human driven factors have dramatically accelerated this process. The overuse and misuse of antibiotics to treat non bacterial infections, their widespread use in agricultural settings, and poor patient adherence to prescribed treatment regimens have together created ideal conditions for resistance to emerge and spread. The U.S. Centers for Disease Control and Prevention estimates that 70 percent of bacterial infections in the country are already caused by pathogens resistant to at least one antibiotic currently on the market.
Most concerning, even last line of defense antibiotics such as Colistin are now ineffective against certain strains, as reported in the Lancet Infectious Disease. This means the medical community is approaching a point where some infections may become entirely untreatable, placing routine surgical procedures such as organ transplants, cesarean sections, and joint replacements at serious risk.
A Drug Pipeline That Has Run Dry
Despite the severity of the antibiotic resistance crisis, financial incentives for developing new antibiotics have continued to shrink. The standard pharmaceutical development model relies on recouping research and development costs through sales during a period of patent exclusivity. For antibiotics, this model breaks down in a fundamental way.
New antibiotics must be reserved for cases of last resort and used as sparingly as possible to preserve their effectiveness. This limits sales volume and makes the return on investment unattractive compared to drugs for chronic conditions. As a result, many large pharmaceutical companies have reduced or eliminated their antibiotic research programs over the past two decades, redirecting resources toward more commercially viable therapeutic areas.
What Incentives Could Reverse the Trend
Experts broadly agree that a combination of push and pull strategies is needed to stimulate antibiotic research and development. Push approaches reduce the upfront financial risk of drug development through research grants, tax incentives, public private partnerships, and shared access to scientific resources. These measures lower the barrier to entry for smaller companies and academic institutions working on novel antibiotic compounds.
Pull strategies, by contrast, reward successful drug development after the fact. Proposed mechanisms include monetary prizes, advanced market commitments, and patent buyouts that guarantee a return regardless of sales volume. The Review on Antimicrobial Resistance specifically called for a global system of market entry rewards of approximately one billion USD per drug developed for areas of most urgent need.
Coordinating these efforts internationally will require a dedicated Global Innovation Fund capable of supporting early stage and non commercial research, forming consortia of universities, small pharmaceutical companies, CROs, and partner organizations to share expertise and accelerate progress on new drug molecules and targets.
Changing Behavior Across the System
Structural and financial reforms alone will not solve antibiotic resistance. Behavioral change at every level of the system is equally essential. One of the most consistently identified challenges is improving patient adherence to antibiotic treatment regimens. Studies repeatedly show that patients frequently stop taking antibiotics before completing a full course, often because symptoms improve before the infection is fully cleared. Incomplete treatment increases the likelihood that resistant strains survive.
Overprescribing is another major driver. Clinicians have historically prescribed antibiotics when the underlying cause of an illness is unclear, partly because doing so is faster and less expensive than waiting for diagnostic results. Developing faster, more affordable, and more reliable diagnostic tools is therefore a critical part of any antibiotic resistance strategy.
In some regions, antibiotics are available without prescription, enabling self medication and incorrect self diagnosis. Reducing over the counter availability and strengthening regulatory oversight in these markets would help lower inappropriate use.
Prevention, Vaccination, and Surveillance
Reducing the overall demand for antibiotics is just as important as developing new ones. Preventing infections from occurring in the first place through improved hygiene, particularly hand washing in healthcare settings, access to clean water and sanitation in lower income countries, and expanded vaccination programs, would substantially reduce the burden of bacterial infections that drive antibiotic use.
Organizations such as Gavi, the Vaccine Alliance, are working to increase vaccine access in lower and middle income countries by pooling demand and reducing costs, bringing more manufacturers into the market and enabling broader immunization coverage.
Ongoing global surveillance of antibiotic use patterns, resistance mechanisms, and emerging threats is also essential for forming effective health policy, guiding emergency responses, and tracking long term trends. For a comprehensive overview of how antibiotic resistance develops and what individuals can do, the Mayo Clinic provides a thorough and accessible resource.
Clinical Research and Infectious Disease Innovation
Developing the next generation of antibiotics and validating new approaches to infection prevention requires a robust clinical research infrastructure. Trials evaluating novel antimicrobial agents, vaccine candidates, and diagnostic technologies depend on experienced sites capable of conducting complex infectious disease studies at scale.
FOMAT supports clinical research across infectious disease and multiple additional therapeutic areas through a national network of investigator sites. To explore active studies, visit our patient active studies page. For more health and research insights, explore the FOMAT blogs and updates.